Osborne Clarke in Amsterdam has advised iOnctura, a clinical stage biopharmaceutical company, developing a pipeline of next generation molecules targeting cancer and fibrosis, in the closing of a EUR 15 million Series A financing.
The financing was led by INKEF Capital and co-led by VI Partners with participation by new investor Schroder Adveq. iOnctura’s founding investor, M Ventures, also participated in the fundraise. iOnctura was founded in 2017 as a spin-out from Merck, with Merck and Cancer Research UK providing a best-in-class pipeline of molecules that harness both direct and immune-mediated anti-cancer activities in solid cancers and cancer fibrosis.
The Osborne Clarke in Amsterdam team was led by Partner Herke van Hulst and consisted of Senior Associate Geoffrey Beurskens, Partners Cars-Jan van Gool (Civil Law Notary) and Job van der Pol (Tax) and Associates Arlette Vrolijk (Candidate Civil-Law Notary), Aram Hovanesjan (Tax) and Florien Sanders (Corporate M&A).
Osborne Clarke has a market-leading international venture capital practice and is widely recognised as a leading European law firm for companies operating in the life science and healthcare sector team. Its sector team has a strong track record of providing highly sophisticated advice to investors and biotech clients on cutting-edge issues, across multiple service lines. They work with blue chip venture capital firms, the biggest pharma and medical devices companies in the market. In 2019, the team advised generic pharmaceutical company Actavis UK Limited and Actavis Ireland Limited on its £603m divestment by Teva Pharmaceutical Industries Ltd to Intas Pharmaceuticals Ltd.